Authorship: S.S. Adam wrote the manuscript and C. Hoppe co-wrote and revised the manuscript.
Article first published online: 31 DEC 2012
Copyright © 2012 Wiley Periodicals, Inc.
Pediatric Blood & Cancer
Volume 60, Issue 4, pages 550–557, April 2013
How to Cite
Adam, S. S. and Hoppe, C. (2013), Potential role for statins in sickle cell disease. Pediatr. Blood Cancer, 60: 550–557. doi: 10.1002/pbc.24443
Conflict of interest: Nothing to declare.
- Issue published online: 13 FEB 2013
- Article first published online: 31 DEC 2012
- Manuscript Accepted: 21 NOV 2012
- Manuscript Received: 25 MAR 2012
- sickle cell disease;
The complex pathophysiology of sickle cell disease (SCD) is remarkably similar to that observed in other chronic vascular diseases and involves multiple biologic pathways triggered by ischemia reperfusion injury, coagulation activation, and inflammation. Statins are potent lipid-lowering agents commonly used to reduce the risk of cardiovascular disease. Independent of their lipid lowering effect, statins have been shown to down-regulate inflammatory mediators and endothelial adhesion molecules, reduce tissue factor expression and restore nitric oxide bioavailability. The pleiotropic effects of statins make these agents attractive therapeutic candidates for SCD. This article reviews available evidence for the potential role of statins in SCD. Pediatr Blood Cancer 2013; 60: 550–557. © 2012 Wiley Periodicals, Inc.